SAA1 and endothelial dysfunction: Given the previous in vitro data which demonstrated the atheroprotective activity of 4-MetT in the context of SAA-mediated endothelial dysfunction, it is hypothesised that, in vivo, prophylactic or therapeutic supplementation of 4-MetT may mitigate pro-oxidative and pro-inflammatory histological markers induced by SAA and therefore may potentially offer renal and cardioprotective benefits.